Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS2881113 A
Publication typeGrant
Publication dateApr 7, 1959
Filing dateJan 29, 1957
Priority dateJan 29, 1957
Publication numberUS 2881113 A, US 2881113A, US-A-2881113, US2881113 A, US2881113A
InventorsMillman Max
Original AssigneeOrtho Pharma Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Therapeutically active compositions containing amphetamines
US 2881113 A
Abstract  available in
Images(2)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent THERAPEUTICALLY ACTIVE COMPOSITIONS CONTAINING AMPHETAMINES Max Millman, Springfield, Mass, assignor 'to' Ortho lyharmaceutical Corporation, a corporation of New ersey N0 Drawing. Application January 29, 1957 Serial No. 636,866

3 Claims. (Cl. 167-55) This invention relates to new and improved compositions consisting of amphetamine compounds and has particular relation to a new and useful therapeutic agent containing the aforementioned compounds. More specifically, the present invention relates to amphetamine compounds such as dl-amphetamine sulfate, dl-amphetamine hydrochloride, dextroamphetamine sulfate, and methamphetamine hydrochloride, combined with critical amounts of an amphoteric antacid such as aluminum hydroxide, magnesium trisilicate, or dihydroxy aluminum aminoacetate. The compositions of my invention are appetite satients effective for the treatment of obesity.

The amphetamines are used not infrequently in the treatment of mental depression, narcolepsy, lethargy and several other conditions. Their most common use, however, is as appetite depressants in the treatment of overweight and obesity.

It is well known that amphetamine compounds such as amphetamine sulfate and hydrochloride, dextroamphetamine sulfate, methamphetamine hydrochloride, etc., act as stimulants for the central nervous system and are capable of exerting valuable effects in the treatment of obesity. However, said compounds have also certain undesirable gastrointestinal effects, such as heartburn, nausea, vomiting, and diarrhea. These symptoms are not infrequently observed in patients receiving amphetamine compounds.

It is the main object of the present invention to provide an amphetamine composition, the beneficial eifects of which are greater and the undesirable side eflfects of which are less than known amphetamine compositions.

It is another object of the present invention to improve the action of amphetamine compounds by buffering or combining them with critical amounts of amphoteric antacids such as aluminum hydroxide, magnesium trisilicate, and dihydroxy aluminum aminoacetate.

Another object of the present invention is to provide a therapeutic agent, the anorexigenic or appetite-depressant effects of which are higher than those of the amphetamines alone.

Still another object of this invention is to reduce the undesirable side effects such as epigastric distress and heartburn which are occasionally encountered with the amphetamines alone.

Other objects and advantages of the invention will be apparent from the appended claims and the following specification which describes by way of example some embodiments of the invention.

I have now discovered that the appetite depressing action of amphetamines may be synergized and the undesirable side efiects of amphetamine compounds reduced by combining or buffering them with critical amounts of certain amphoteric antacids. More specifically, the novel appetite satient composition of the present invention includes, in addition to the amphetamine compound or mixture of amphetamine compounds, at least 8 milli-equivalents of a mixture of aluminum hy- 2 dioxide, magnesium trisilicate, and dihydroxyaluminum aminoacetate.

The amphetamine compound which I have found effective in my compositions is dextroamphetamine (dextro-l-phenyl-2-aminopropane). It is known that this compound is more effective when mixed with the dlamphetamine. I prefer to use in a single dosage unit approximately 3 mgm. of an amphetamine compound such as dextroamphetamine sulfate together with 3 mgm. of dl-amphetamine sulfate. To this I add at least .8- milliequivalents of a mixture of aluminum hydroxide and magnesium trisilicate. To minimize the occasional undesirable stimulation of the nervous system caused by administering amphetamine compounds, I may. add to my composition a sedative such as amytal (5-ethy1-5- isoamyl barbituric acid), barbital. (5,5'-diethyl barbituric acid), or phenobarbital 5-ethyl-5'-phenyl barbituric acid) in variable doses.

Because of their amphoteric character, there is no critical limitation on the maximum amount of antacid that is present in my compositions. As magnesium trisilicate is a laxative and large amounts of aluminum hydroxide would cause constipation, it is desirable 'to combine these two antacids. Satisfactory compositions prepared according to this invention contain about two or three parts by weight of magnesium trisilicate to one part by weight of aluminum hydroxide. Dihydroxy= aluminum amino'acetate may be substituted in whole or in part for the aluminum hydroxide.

My compositions may more conveniently be used i171 the form of tablets of lozenges (pleasant tasting). The

tablets may be prepared by mixing the active'ingredients (amphetamine compounds, barbiturates, magnesium trisilicate, and aluminum hydroxide) with excipients (sugar, talc, corn starch and binders) and flavoring oils (oil of peppermint, oil of fennel and methyl salicylate). The tablet may be prepared by processes well known in the pharmaceutical line, such as by slugging or by a wet granulation process. Lozenges containing similar dosage of active ingredients may also be prepared by known methods. It is an advantage of the lozenges that they' may be chewed and swallowed without the aid of water.

As the amphetamines are most effective when taken about one-half to one hour before meals when water is not always readily available for administration, the lozenges are a most convenient dosage form.

Granulate part A with 10% gelatin solution and dry at 50 C. Regranulate and mix with B. Compress into tablets weighing 1183.5 mgm.

EXAMPLE II Ingredient: Per tablet, mgm. A. Dextroamphetamine sulfate 3.5 Methamphetamine hydrochloride 1.5 Amytal 20.0 Aluminum hydroxide 110.0 Magnesium trisilicate 350.0

B. Starch 4.25 Magnesium stearate 4.25

Granulate part A with 10% gelatin solution. Dry at Compress .into

with the exception that the aluminum hydroxide and magnesium trisilicate were omitted. The amphetamines were in the same dosage as noted for group I.

The 10 patients in group III were a control group. These patients received antacids (aluminum hydroxide and magnesium trisilicate) alone.

The clinical results are tabulated in Table I.

Table 1 Average Number Total lbs. lost Group of Treatment lbs. lost, per

patients 8 wks. patlent per week I 26 Amphetamines and antacids... 479 2. 30 II 26 Amphetamines alone 261 1. III..... 10 Antacids alone 0 It is apparent that there is a significant difference in the degree of weight loss induced by the three treatments. It may be noted that the antacids have no appetite-depressing action. Since, however, upon combination with amphetamines the anorexigenic effect of the latter was enhanced, it may be concluded that the antacids pro- EXAMPLE .111 Ingredient: Per tablet, mgm. A. Dextroamphetamine sulfate up 5.0 Amytal 15.0 Aluminum hydroxide 250.0 Magnesium trisilicate 500.0 B. Starch 4.25 Magnesium stearate 4.25 -Granulate part A with 10% gelatin solution and dry at 50 C. Regranulate and mix with B. Compress into tablets weighing 778.5 mgm.

EXAMPLE IV Ingredient: Per tablet, mgm. AJBextroamphetamine sulfate 3.0 dl-Amphetamine sulfate 3.0 Amytal 30.0 Aluminum hydroxide 110.0 Magnesium trisilicate 600.0 Dixhydroxy aluminum aminoacetate 300.0 E. Sucrose 1000.0

I Granulate part A with 10% gelatin solution and dry at ,50' C. Regranulate and mix with B. Compress into lozenges weighing 2,046 mgm.

"The proportions of the various ingredients of my composition may be varied widely. The amphetamine comperiod may vary from about 3 to about 6 mgm. per dosage unit. The barbiturate may be eliminated entirely or may be present in an amount up to approximately mgm. The lower limit of the amphoteric antacid is critical as too small an amount is not effective. I have found that at least 4 milli-equivalents of aluminum hydroxide (104 mgm.) in combination with at least 4 mini-equivalents of magnesium trisilicate (350 mgm.) is required to synergize the appetite depressing action of amphetamines. An equivalent amount of dihydroxy aluminum aminoacetate may be substituted for the aluminum hydroxide. Since the amphoteric antacids employed are non-toxic, the upper limit of the amount of antacid present is not critical.

"The practical effect of my amphetamine compositions may be appreciated from clinical results on 62 unselected overweight patients ranging in age from 17 to 72 years and in weight from 132 to 291 pounds. These patients were divided into three groups and treated for a period of eight weeks. The 26 patients in group I were treated with tablets prepared according to Example I. Dosage wasthre'e tablets daily about one-half to one hour before meals, yielding a total of 15 mgm. of amphetamines perday.

Group II also consisted of 26 patients similarly treated What is claimed is:

duced a synergistic effect with the amphetamines. Experimental findings in laboratory animals corroborate this observation.

In addition to the better results observed with the use of aluminum hydroxide and magnesium trisilicate, the patients in group I reported less hunger and fewer gastrointestinal side effects such as heartburn, nausea, vomiting and diarrhea.

1. An obesity control composition suitable for oral administration comprising in the following relative proportions, 3-4 mgm. of a dextroamphetamine compound, 1-2 mgm. of d-methamphetamine hydrochloride, 0-20 mgm. of S-ethyl-S-isoamyl barbituric acid, 4 milli-equivalents of aluminum hydroxide, and 4 milli-equivalents of magnesium trisilicate.

2. An obesity control composition suitable for oral administration comprising in the following relative pro-. portions, 3 mgm. of dextroamphctamine sulfate, 3 mgm. of dl-amphetamine hydrochloride, 20 mgm. of S-ethyl-S- isoamyl barbituric acid, 350 mgm. of aluminum hydroxide, and 800 mgm. of magnesium trisilicate.

3. An obesity control composition suitable for oral of a mixture of amphetamine compounds and at least 8 milli-equivalents of a mixture of aluminum hydroxide and magnesium trisilicate.

References Cited in the file of this patent Wilson: The American Drug Index, 1956, Lippincott Co., Philadelphia, Pa., PP. 292 and 337.

Non-Patent Citations
Reference
1 *None
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3369967 *Nov 20, 1963Feb 20, 1968Lab D Analyses Et De Rech S BiCompositions for treating obesity and methods of use
US4581232 *Jul 20, 1983Apr 8, 1986Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates
US4632821 *Dec 19, 1985Dec 30, 1986Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of decongestants
US4632822 *Dec 19, 1985Dec 30, 1986Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4632823 *Dec 19, 1985Dec 30, 1986Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of appetite suppressants
US4642231 *Dec 19, 1985Feb 10, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4643892 *Dec 19, 1985Feb 17, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of analgesics
US4643898 *Dec 19, 1985Feb 17, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of nutritional supplements and laxatives
US4647449 *Dec 19, 1985Mar 3, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of alkaloids
US4647450 *Dec 19, 1985Mar 3, 1987Warner-Lambert CompanyChewing gum compositions containing magnesium trisilicate absorbates
US4647459 *Dec 19, 1985Mar 3, 1987Warner-Lambert CompanyConfectionery compositions containing magnesium trisilicate adsorbates
US4649041 *Dec 19, 1985Mar 10, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US4650663 *Dec 19, 1985Mar 17, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US7772222Feb 8, 2008Aug 10, 2010Mickle Travis CPolar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
US7776917Dec 10, 2007Aug 17, 2010Mickle Travis CNon-standard amino acid conjugates of amphetamine and processes for making and using the same
US8101661Jul 26, 2010Jan 24, 2012Kempharm, Inc.Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same
US8846100May 12, 2006Sep 30, 2014Shire LlcControlled dose drug delivery system
US9173857Sep 26, 2014Nov 3, 2015Shire LlcControlled dose drug delivery system
US20040219213 *Jan 16, 2004Nov 4, 2004Burnside Beth A.Oral pulsed dose drug delivery system
US20060127473 *Dec 13, 2005Jun 15, 2006Nichols William MCompositions and methods for stabilizing active pharmaceutical ingredients
US20070264323 *May 12, 2006Nov 15, 2007Shire LlcControlled dose drug delivery system
US20080139653 *Dec 10, 2007Jun 12, 2008Mickle Travis CNon-standard amino acid conjugates of amphetamine and processes for making and using the same
US20080207757 *Feb 8, 2008Aug 28, 2008Mickle Travis CPolar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same
US20100292336 *Jul 26, 2010Nov 18, 2010Mickle Travis CPolar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same
US20100292337 *Jul 26, 2010Nov 18, 2010Mickle Travis CPolar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same
USRE42096 *Mar 24, 2005Feb 1, 2011Shire LLC, USAOral pulsed dose drug delivery system
WO2008073918A1 *Dec 10, 2007Jun 19, 2008Kempharm, Inc.Non-standard amino acid conjugates of amphetamine and processes for making and using the same
Classifications
U.S. Classification424/683, 424/690
International ClassificationA61K45/00
Cooperative ClassificationA61K45/00
European ClassificationA61K45/00